Opendata, web and dolomites

CG-100

A next generation medical device that enhances patient care and treatment following colorectal surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CG-100 project word cloud

Explore the words cloud of the CG-100 project. It provides you a very rough idea of what is the project "CG-100" about.

infections    surgery    patient    50    silicon    diseases    advisors    company    stoma    healthcare    prevent    ce    device    trials    faecal    bags    solution    cg    team    diverting    employ    ostomy    parastomal    employees    patients    economic    waste    site    threatening    2010    companies    intraluminal    active    contact    internal    time    life    doctors    pains    received    cancer    stage    leakage    proprietary    entrepreneurs    single    moving    sepsis    israel    leads    anastomotic    complication    stomas    comprising    al    shown    healing    mark    bag    confidently    founded    leaks    place    multiple    bypass    ltd    chronic    date    talks    dec    profound    subcontractors    complications    reducing    medical    clinical    risky    external    colorectal    cologuard    2014    skin    functions    care    procedure    colonic    eur    marketing    headquartered    ulcers    surgeons    improves    vast    hernia    quality    causing    content    anastomosis    depression    full   

Project "CG-100" data sheet

The following table provides information about the project.

Coordinator
COLOSPAN LTD 

Organization address
address: 21 ATIR YEDA STREET
city: KFAR SABA
postcode: 4464316
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.cologuard.co.il
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COLOSPAN LTD IL (KFAR SABA) coordinator 50˙000.00

Map

 Project objective

Cologuard Ltd is a clinical stage medical device company founded in Dec 2010. Cologuard's novel and proprietary technology for colorectal surgery was developed in order to prevent the profound clinical and economic pains associated with anastomotic leaks and diverting colonic stomas. Anastomotic leakage (AL) is a life threatening complication, which can occur following colorectal surgery for colorectal cancer or other diseases. In order to prevent AL, surgeons use a procedure called diverting stoma, which result in an ostomy bag for external bypass of waste. This solution leads to a low quality of life for patients, causing many clinical complications, including sepsis, parastomal hernia, ulcers, chronic depression and skin infections. In addition, this procedure has a high economic cost for the patient and the healthcare system. The Cologuard team have developed the CG-100, a single use intraluminal device composed of silicon, which functions as an internal bypass for colonic content, reducing contact between faecal content and the anastomosis site. The device allows healing to take place without the need for an external diverting stoma and ostomy bag. The CG-100 device improves patient care through the reduction of risky complications associated with ostomy bags, improving the healing process and providing a better quality of life. Healthcare costs will be greatly reduced by up to 50%. The company is composed of a strong team comprising top doctors and medical advisors as well as entrepreneurs with vast experience in the medical device sector. The company received CE mark for its lead product in 2014 and is confidently moving towards pre-marketing clinical trials in the EU. Cologuard has received over 4.2 M EUR funding to date. The company is headquartered in Israel and employ 5 full time employees and multiple subcontractors. The company is currently in talks with companies in the EU who have shown an active interest in the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CG-100" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CG-100" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More